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Abstract
Background: Tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7),
inducers of G1 cell cycle arrest, are two recently discovered good biomarkers for early diagnosis of acute kidney injury (AKI).
To obtain a more robust performance measurement, the present meta-analysis was performed, pooling existing studies.
Methods: Literature in the MEDLINE (via PubMed), Ovid, Embase, and Cochrane Library databases was systematically
searched from inception to 12 October 2016. Studies that met the set inclusion and exclusion criteria were identified by
two independent investigators. The diagnostic value of urinary [TIMP-2] × [IGFBP7] for AKI was evaluated by pooled
sensitivity, specificity, likelihood ratio (LR), diagnostic odds ratio (DOR), and summary receiver operating characteristic
(SROC) curve analyses. The causes of heterogeneity were explored by sensitivity and subgroup analyses.
Results: A total of nine published and eligible studies assessing 1886 cases were included in this meta-analysis. Early
diagnostic value of urinary [TIMP-2] × [IGFBP7] for AKI was assessed using a random-effects model. Pooled sensitivity
and specificity with corresponding 95% CIs were 0.83 (95% CI 0.79–0.87, heterogeneity I2 = 68.8%) and 0.55 (95% CI 0.
52–0.57, I2 = 92.9%), respectively. Pooled positive LR, negative LR, and DOR were 2.37 (95% CI 1.87–2.99, I2 = 82.6%), 0.30
(95% CI 0.21–0.41, I2 = 43.4%), and 9.92 (95% CI 6.09–16.18, I2 = 38.5%), respectively. The AUC estimated by SROC was 0.
846 (SE 0.027) with a Q* value of 0.777 (SE 0.026). Sensitivity analysis indicated that one study significantly affected the
stability of pooled results. Subgroup analysis showed that population setting and AKI threshold were the key factors
causing heterogeneity in pooled sensitivity and specificity.
Conclusions: On the basis of recent evidence, urinary [TIMP-2] × [IGFBP7] is an effective predictive factor of AKI.
Trial registration: PROSPERO registration number: CRD42016051186. Registered on 10 November 2016.
Keywords: Tissue inhibitor of metalloproteinase-2, Insulin-like growth factor binding protein 7, Acute kidney
injury, Diagnosis
Background
Acute kidney injury (AKI) is a common disorder of crit-
ically ill patients, especially in the intensive care unit
(ICU), and a potential life-threatening factor closely as-
sociated with prolonged ICU stay, severe complications,
and increased mortality. Prevention and identification of
AKI in the early stage is important for improving the
prognosis of critically ill patients [1, 2]. Although consid-
ered a standard tool in clinical routine tests, serum cre-
atinine and urine output are not suitable for the early
detection of AKI, owing to inherent methodological
problems [3, 4]. Novel biomarkers for detecting AKI
(i.e., neutrophil gelatinase-associated lipocalin [NGAL],
kidney injury molecule-1 [KIM-1], and liver-type fatty
acid-binding protein [L-FABP]) show earlier recognition
of AKI [5–7]. Notably, urinary tissue inhibitor of
metalloproteinase-2 (TIMP-2) and insulin-like growth
factor-binding protein 7 (IGFBP7) were recently discovered
* Correspondence: liwx1126@163.com
Department of Surgical Intensive Care Unit, Beijing Chao-yang Hospital,
Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District,
Beijing 100020, China
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jia et al. Critical Care  (2017) 21:77 
DOI 10.1186/s13054-017-1660-y
and considered to be superior to NGAL, KIM-1, and
L-FABP [8]. Both TIMP-2 and IGFBP7 are inducers of G1
cell cycle arrest, considered a key mechanism of AKI [9].
Kashani and colleagues [8] conducted the Stenting and
Angioplasty with Protection in Patients at High Risk for
Endarterectomy study to identify and validate novel
biomarkers of AKI. The results showed that urinary
[TIMP-2] × [IGFBP7] yields an AUC of 0.8 for predicting
the development of AKI (Kidney Disease: Improving Global
Outcomes [KDIGO] stage 2 or 3) within 12 h, indicating its
superiority over 340 previously studied AKI proteins. Fur-
thermore, other studies confirmed the good predictive per-
formance of urinary [TIMP-2] × [IGFBP7] for AKI [10, 11].
Therefore, the present meta-analysis was performed
to obtain a more robust performance measurement of
[TIMP-2] × [IGFBP7] for early detection of AKI with
more reliable evidence for clinical decision making.
Methods
Data sources and search strategy
A protocol of complete meta-analysis was constructed
and adhered to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) standards
[12]. The protocol was registered with the PROSPERO
database (registration number CRD42016051186).
Two investigators (HMJ and LFH) independently
searched the literature in the MEDLINE (via PubMed
search engine), Ovid, Embase, and Cochrane Library
electronic databases from inception to 12 October 2016.
Text words or medical subject headings containing “tis-
sue inhibitor of metalloproteinase-2,” “TIMP-2,” “insu-
lin-like growth factor binding protein 7,” “IGFBP7,”
“acute kidney injury,” “AKI,” “acute renal failure,” “ARF,”
“acute kidney disease,” and “acute kidney stress” were
researched without language restriction. Additional stud-
ies were identified by reviewing the reference lists of
relevant articles.
Study selection criteria
Two investigators (HMJ and LFH) independently
screened the records obtained from the databases. Stud-
ies were included if they met the following three criteria:
1. Original clinical studies with participants over the
age of 18 years (without restriction for study design)
2. Detection of urinary [TIMP-2] × [IGFBP7] used for
early diagnosis of AKI
3. Development of AKI diagnosed by the criteria of
risk, injury, failure, loss, end-stage kidney disease
(RIFLE); the Acute Kidney Injury Network; or
KDIGO [13–15]
Original human studies were excluded if they had insuf-
ficient information for true-positive (TP), false-positive
(FP), false-negative (FN), and true-negative (TN) results.
Repeated reports based on the same study data were also
excluded. All retrieved articles were initially screened by
title and abstract. The relevant ones were subsequently
rescreened by full text. A third party resolved any discrep-
ancies between two investigators (HMJ and LFH) in the
process of study selection.
Data extraction and quality assessment
Two investigators (HMJ and LFH) independently ex-
tracted study characteristics and data from individual re-
ports, including first author, year of publication, study
location, study design, population setting, AKI definition,
sample size, sampling time of urine specimens, assay of
urine TIMP-2 and IGFBP7, and numbers of AKI and
non-AKI patients. Meanwhile, TP, FP, FN, TN, sensitiv-
ity, specificity, AUC, and optimal cutoff value of urinary
[TIMP-2] × [IGFBP7] for early diagnosis of AKI were re-
corded. If multiple time points of urine measurements
were used for AKI diagnosis, the one with the highest
AUC was recorded. Similarly, if multiple cutoff values
were obtained via AUC analysis, the one showing the
highest Youden index was recorded.
Two investigators (HMJ and LFH) independently
assessed the methodological quality of eligible studies
using the Quality Assessment of Diagnostic Accuracy
Studies 2 (QUADAS-2) tool [16]. QUADAS-2, focusing
on risk of bias in the accuracy and applicability of ori-
ginal articles, consists of four domains: patient selection,
index test, reference standard, and flow and timing. Each
domain assesses the risk of bias by representative ques-
tions whose corresponding answers may be “yes,” “no,”
or “unclear.” If all answers were “yes” in one domain,
low risk of bias was considered. Any “no” in one domain
indicated a high risk of bias. Studies not providing suffi-
cient information to answer “yes” or “no” in the domain
reflected unclear risk of bias. Methods used to assess the
applicability of studies are the same as those of risk of
bias. A third party resolved any discrepancies between
two investigators (HMJ and LFH) in the process of data
extraction and quality assessment.
Statistical analysis
Meta-DiSc 1.4 software was used for statistical analysis.
A random-effects model (DerSimonian and Laird method)
or fixed-effects model (Mantel-Haenszel method) was
constructed to estimate pooled sensitivity, specificity, posi-
tive likelihood ratio (PLR), negative likelihood ratio (NLR),
and diagnostic odds ratio (DOR) with 95% CI. Model se-
lection was based on the heterogeneity of included studies
[17, 18]. Heterogeneity induced by threshold effect was
reflected by a typical shape of a “shoulder-arm” in the
summary receiver operating characteristic (SROC) plane
or p < 0.05 in Spearman’s correlation coefficient test.
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Heterogeneity induced by a nonthreshold effect was evalu-
ated by Cochran’s Q test and I2 test; Cochran’s Q test with
p < 0.10 indicated heterogeneity, whereas different I2
values reflected low (<30%), moderate (30% to 50%), and
high (>50%) degrees of heterogeneity. To identify the
causes of heterogeneity in eligible studies, sensitivity and
subgroup analyses were performed. The stability of results
was examined by omitting one study at a time in sensitiv-
ity analysis; different subgroups based on potential sources
of heterogeneity were considered in subgroup analysis.
The SROC curve was used to estimate AUC [19], with a
value ≥0.70 considered to reflect a useful predictive factor.
Publication bias was assessed via funnel plot using Review
Manager 5.3 software [20].
Results
Study selection and characteristics
A flow diagram summarizing the study selection process
is presented in Fig. 1. A total of 110 related reports were
initially obtained from the databases, including 44 from
PubMed, 27 from Ovid, 37 from Embase, and 2 from
Cochrane Library. After removing duplicates, 63 articles
were screened by title and abstract. Twenty-four hits
were subsequently rescreened by full text after exclusion
of 39 reports. Finally, 9 eligible studies assessing 1886
cases were included in this meta-analysis summarizing
the predictive value of urinary [TIMP-2] × [IGFBP7] for
AKI. The nine prospective cohort studies were published
from 2013 to 2016, with sample sizes between 40 and
728. Most of them were conducted in the United States
and Germany, with a cutoff value of 0.3 (ng/ml)2/1000.
Notably, population settings were different in the nine
studies, including postoperative cardiac patients, critic-
ally ill individuals in the ICU, and patients in the emer-
gency department (ED) [7, 21–28]. The full KDIGO
criteria were used to diagnose AKI in all nine studies,
but AKI thresholds were different. Three studies defined
primary clinical endpoint as patients meeting KDIGO
stage 1 criteria. The remaining six studies considered
the primary endpoint as patients meeting KDIGO stage
2 or 3 criteria. Urinary [TIMP-2] × [IGFBP7] was evalu-
ated for AKI prediction within 12 h in four studies, within
48 h in four studies, and within 72 h in one study. The
characteristics of individual studies are shown in Table 1.
Quality assessment
Study quality concerning each domain for individual
studies is depicted in Fig. 2. Funnel plot (Fig. 3) results
indicated a publication bias in the included studies.
Data synthesis
Data extracted from the nine eligible studies are summa-
rized in Table 2. Studies showed different sensitivities, spec-
ificities, and AUC values of urinary [TIMP-2] × [IGFBP7]
for early diagnosis of AKI. AUC values in these studies
ranged from 0.71 to 0.97. Spearman’s correlation coefficient
Fig. 1 Study flow diagram. A diagram summarizing the search and screening process of the included studies. AKI Acute kidney injury
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was 0.46 with p > 0.05, indicating there was no signifi-
cant threshold effect in the nine studies. This result
was also confirmed by the shape without a “shoulder-
arm” in the SROC plane. In assessing the nonthres-
hold effect, pooled DOR (I2 = 38.5%) and NLR
(I2 = 43.4%) showed moderate heterogeneity, whereas
sensitivity (I2 = 68.8%), specificity (I2 = 92.9%), and
PLR (I2 = 82.6%) indicated significantly high hetero-
geneity. A random-effects model was used to pool the
data. Pooled sensitivity and specificity were 0.83 (95%
CI 0.79–0.87) and 0.55 (95% CI 0.52–0.57), respectively.
Pooled PLR, NLR, and DOR were 2.37 (95% CI 1.87–
2.99), 0.30 (95% CI 0.21–0.41), and 9.92 (95% CI 6.06–
16.18), respectively. Estimated AUC was 0.846 (SE 0.027)
with Q* of 0.777 (SE 0.026). The pooled sensitivity, specifi-
city, PLR, and NLR for the nine studies are presented in
Fig. 4.
In sensitivity analysis, the study by Dusse and col-
leagues [28] could affect the stability of pooled results.
Omitting this study, the heterogeneity of pooled DOR
decreased from moderate to low degree, with I2 index
decreasing from 38.5% to 28.0%. A slight reduction of I2
was found in pooled specificity, PLR, and DLR. Pooled
sensitivity, specificity, PLR, NLR, and DOR were 0.83
(95% CI 0.78–0.87, I2 = 69.1%), 0.54 (95% CI 0.51–0.56,
I2 = 92.4%), 2.15 (95% CI 1.74–2.65, I2 = 79.3%), 0.31
(95% CI 0.22–0.42, I2 = 42.5%), and 8.97 (95% CI
5.78–13.91, I2 = 28.0%), respectively. The estimated AUC
was 0.839 (SE 0.028) with Q* of 0.771 (SE 0.026). A
comparison of pooled DOR and SROC curves between
eight and nine studies is shown in Fig. 5. Pooled sensitiv-
ity, specificity, PLR, and NLR for the eight studies are
presented in Fig. 6.
Subgroup analysis was conducted based on population
setting, AKI threshold, and blinding status. The results
showed that population setting and AKI threshold were
key factors causing heterogeneity. The 9 studies were di-
vided into two subgroups according to different popula-
tion settings. A total of 4 studies focused on patients
undergoing cardiac surgery, and were termed the “car-
diac surgery” subgroup. 4 others focused on patients in
the ICU and 1 on patients in the ED, and constituted
the “ICU and ED” subgroup. Interestingly, urinary
[TIMP-2] × [IGFBP7] showed an excellent diagnostic
value in patients undergoing cardiac surgery with esti-
mated AUC of 0.911. Pooled sensitivity and specificity
were 0.75 (95% CI 0.62-0.86, I2 = 69.8%) and 0.87 (95%
CI 0.80-0.92, I2 = 33.9%), respectively. In the “ICU and
ED” subgroup, estimated AUC was 0.814; pooled sensi-
tivity and specificity were 0.85 (95% CI 0.80-0.89, I2 =
68.5%) and 0.51 (95% CI 0.49-0.54, I2 = 89.2%), respect-
ively. Similarly, the 9 studies were divided into “KDIGO
stage 2 or 3” and “KDIGO stage 1” subgroups according
to the different AKI thresholds mentioned above. There
were 6 studies in the “KDIGO stage 2 or 3” subgroup;
estimated AUC was 0.813, while pooled sensitivity and
specificity were 0.88 (95% CI 0.83-0.91, I2 = 38.9%) and
0.52 (95% CI 0.49-0.55, I2 = 89.8%), respectively. There
were 3 studies in the “KDIGO stage 1” subgroup; esti-
mated AUC was 0.868, with pooled sensitivity and speci-
ficity of 0.70 (95% CI 0.59-0.79, I2 = 54.3%) and 0.88
(95% CI 0.80-0.93, I2 = 31.7%), respectively. The results
of subgroup analysis are shown in Table 3.
Fig. 2 Quality assessment summary in each domain for individual
studies. The quality assessment focusing on risk of bias and applicability
concerns consists of four domains, including “patient selection,” “index
test,” “reference standard,” and “flow and timing.” Green, yellow, and red
indicate low, moderate, and high risk of bias, respectively
Fig. 3 Funnel plot for the identification of potential publication bias
in the included studies. DOR Diagnostic odds ratio
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Discussion
AKI remains one of the most common and serious clin-
ical syndromes, and it is associated with high morbidity
and mortality in critically ill patients. Current diagnosis
of AKI is based on serum creatinine and urine output,
despite known limitations of these markers. Diverse plat-
forms and multiple studies have explored future bio-
markers for early prediction of AKI [29]. In order to
obtain a more robust performance measurement of urin-
ary [TIMP-2] × [IGFBP7] for AKI, this meta-analysis was
performed, also pooling existing studies. A total of 9
published and eligible studies assessing 1886 cases were
included. The results indicated that urinary [TIMP-
2] × [IGFBP7] is an effective predictive factor of AKI.
Dusse and colleagues demonstrated an excellent
predictive value of urinary [TIMP-2] × [IGFBP7] for
AKI in patients undergoing transcatheter aortic valve
implantation (TAVI). An AUC of 0.97 was obtained,
with sensitivity and specificity of 100% and 91%, re-
spectively. However, sensitivity analysis showed that
this study could result in significant heterogeneity in
pooled DOR. Its small sample size and the specific
population setting were considered important issues
that can lead to heterogeneity. On one hand, the
small sample size of 40 patients was likely to cause
publication bias. On the other hand, patients under-
going TAVI are at high risk of developing AKI, which
is probably associated with hypotension occurrence,
Table 2 Diagnostic value of urinary [TIMP-2] × [IGFBP7] for acute kidney injury in individual studies
First author, year
[reference]





valueTP FP FN TP
Kashani, 2013 [8] 90 313 11 314 0.89 (0.81–0.94) 0.50 (0.46–0.54) 0.80 0.3
Bihorac, 2014 [21] 65 182 6 155 0.92 (0.83–0.97) 0.46 (0.41–0.51) 0.82 0.3
Hoste, 2014 [22] 24 59 3 67 0.89 (0.71–0.98) 0.53 (0.44–0.62) 0.79 0.3
Meersch, 2014 [23] 21 4 5 20 0.81 (0.61–0.93) 0.83 (0.63–0.95) 0.81 0.3
Wetz, 2015 [24] 8 1 8 25 0.50 (0.25–0.75) 0.96 (0.80–1.00) 0.71 1.07
Pilarczyk, 2015 [25] 5 10 1 44 0.89 (0.36–1.00) 0.81 (0.69–0.91) 0.82 0.89
Gocze, 2015 [26] 32 9 13 53 0.71 (0.56–0.84) 0.85 (0.74–0.93) 0.85 0.3
Kimmel, 2016 [27] 35 118 11 134 0.76 (0.61–0.87) 0.53 (0.47–0.59) 0.76 0.3
Dusse, 2016 [28] 8 3 0 29 1.00 (0.63–1.00) 0.91 (0.75–0.98) 0.97 1.03
Abbreviations: IGFBP7 Insulin-like growth factor-binding protein 7, TIMP-2 Tissue inhibitor of metalloproteinase-2; TP True-positive, FP False-positive, FN False-negative,
TP True-negative
Fig. 4 Sensitivity, specificity, positive likelihood ratio (LR) and negative LR of urinary [TIMP-2] × [IGFBP7] for predicting acute kidney injury in the
nine studies. a Sensitivity. b Specificity. c Positive LR. d Negative LR. IGFBP7 Insulin-like growth factor-binding protein 7, TIMP-2 Tissue inhibitor
of metalloproteinase-2
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Fig. 5 Pooled diagnostic OR (DOR) and summary receiver operating characteristic (SROC) curves of urinary [TIMP-2] × [IGFBP7] for acute kidney injury
prediction. A comparison of pooled DOR and SROC curves between nine and eight studies. a Pooled DOR in nine studies. b Pooled DOR in eight
studies. c SROC curve of nine studies. d SROC curve of eight studies. IGFBP7 Insulin-like growth factor-binding protein 7, TIMP-2 Tissue inhibitor
of metalloproteinase-2
Fig. 6 Sensitivity, specificity, positive likelihood ratio (LR) and negative LR of urinary [TIMP-2] × [IGFBP7] for acute kidney injury prediction in eight studies.
a Sensitivity. b Specificity. c Positive LR. d Negative LR. IGFBP7 Insulin-like growth factor-binding protein 7, TIMP-2 Tissue inhibitor of metalloproteinase-2
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reduced renal blood flow, and the use of contrast
media during surgery [30, 31].
Subgroup analysis indicated that different population
settings and AKI thresholds were the main sources of
heterogeneity. Urinary [TIMP-2] × [IGFBP7] had a
strong diagnostic value with an estimated AUC of 0.911
in the early stage of cardiac surgery-associated AKI.
There are studies indicating that cardiac surgery with
cardiopulmonary bypass could lead to reduced renal
blood flow as well as surgical trauma, which probably
damage kidney function or structure [32, 33]. Fortu-
nately, with the development of innovative technologies
such as renal Doppler ultrasound, renal blood flow and
cortical microcirculation can be dynamically monitored
at the bedside, which may help manage hemodynamics
and decrease the incidence of ischemic AKI [34]. Further
clinical trials are still required to confirm the diagnostic
value of urinary [TIMP-2] × [IGFBP7] for AKI in pa-
tients undergoing noncardiac surgery.
The diagnostic value of urinary [TIMP-2] × [IGFBP7]
was also influenced by different AKI thresholds. AUC
was higher in the KDIGO stage 1 subgroup than in the
KDIGO stage 2 or 3 subgroup (0.868 vs. 0.813). How-
ever, pooled sensitivity was lower in the KDIGO stage 1
(0.70) compared with that of the KDIGO stage 2 or 3
subgroup (0.88). The main causes may be that TIMP-2
and IGFBP7, reflecting the stress status of the kidney,
are more relevant to kidney damage. AKI diagnosed by
KDIGO stage 1 criteria, possibly with FP results, is
affected by many factors of hemoconcentration, drugs,
and reversible oliguria, which may not develop real
kidney stress and damage. Although KDIGO stage 2 or 3
reflects a moderate to severe AKI, renal cells are more
likely to sustain insults by sepsis and ischemia that cause
kidney damage [35, 36]. On the basis of this hypothesis,
urinary [TIMP-2] × [IGFBP7] may be more sensitive for
predicting AKI with KDIGO stage 2 or 3 than AKI with
KDIGO stage 1.
TIMP-2 and IGFBP7 are two biomarkers of G1 cell cycle
arrest, indicating a preinjury status that leads to AKI [36].
AKI is related to the mechanisms of inflammation, oxida-
tive stress, and apoptosis in cellular and molecular path-
ways [37, 38]. TIMP-2 and IGFBP7 can participate in
these mechanisms and reflect early damage of the kidney
[35]. They can regulate the activated p-protein cascade of
p53, p21, and p27, subsequently blocking the effect of
cyclin-dependent protein kinase complexes and altering
the cellular response to the toxin or inflammatory factors
[39–41]. Moreover, these two biomarkers may attempt to
protect renal cells and avoid division, demise, or senes-
cence [42, 43]. There is evidence showing that TIMP-2
and IGFBP7 are able to mark injured tubular epithelium
and send signals in case of septic and ischemic insults,
warning for kidney stress [44]. Then, renal tubular cells
would enter for a short period G1 cell cycle arrest to pre-
vent injury aggravation [45, 46]. Such physiopathological
mechanisms and cellular pathways may help explain the
use of these markers in early prediction of AKI. Further,
the TOPAZ study recognized that combining urinary
[TIMP-2] × [IGFBP7] with clinical factors could improve
the predictive value in AKI compared with the biomarkers
alone [21]. The AUC of combined urinary [TIMP-
2] × [IGFBP7] and clinical information model was 0.86
(95% CI 0.80–0.90), higher than that of the clinical infor-
mation model alone (AUC 0.70, 95% CI 0.63–0.76) and
the urinary [TIMP-2] × [IGFBP7] test alone (AUC 0.82,
95% CI 0.76–0.88) [21]. These results suggested that a
combination of clinical characteristics with specific bio-
markers may enhance diagnostic accuracy in AKI. Like
troponin, it constitutes an outstanding acute coronary
syndrome biomarker when combined with typical symp-
toms and angina pectoris in specific populations. Simi-
larly, there is renal angina (RA) in the AKI disorder. RA
incorporates risk factors (e.g., advanced age, cardiopulmo-
nary bypass, volume depletion, nephrotoxins) and sympto-
mology (e.g., change of serum creatine, urine output, fluid
overload) of patients to assess risk stratification for adult
AKI. The renal angina index (RAI) is used for pediatric
cohorts instead of RA to evaluate the risk for developing
AKI by establishing point values [47, 48]. Clinical studies
confirmed that a combined use of AKI biomarkers with
RAI could improve the predictive value of the biomarkers
for AKI [49]. Therefore, to a certain extent, this approach
may be considerably potent for early prediction of AKI.
Serum creatinine and urine output were proposed by
KDIGO for diagnosing AKI [15]. However, their use may
inevitably result in inaccurate diagnosis of patients with
AKI. Serum creatinine is readily available and specific for
renal function. Nonetheless, it remains limited for AKI
diagnosis. Serum creatinine can be affected by several fac-
tors, including age, diet, muscle mass, drugs, and creati-
nine’s volume of distribution. With a delayed reaction,
serum creatinine concentrations take 24 to 36 h to rise
after kidney damage. Urine output is far less specific and
can be influenced by diuretics; it persists until renal func-
tion almost ceases. Severe AKI can present as anuria, oli-
guria, and normal urine output, and oliguria can occur in
volume depletion without AKI [13, 50, 51]. Such problems
may result in the limitation of using serum creatinine and
urine output as the gold standard for diagnosing AKI. Fur-
thermore, other limitations also existed in this meta-
analysis. First, urinary [TIMP-2] × [IGFBP7] had a high
predictive value for AKI in different population settings,
but its predictive value was not identified in septic AKI,
owing to limited studies. Second, with various sampling
times in different studies, we did not explore the time
window of urinary [TIMP-2] × [IGFBP7] for the diagnosis
of AKI based on the same population. Third, we included
Jia et al. Critical Care  (2017) 21:77 Page 9 of 11
some studies of small sample size, which could affect
consistency in eligible studies and cause bias. Fourth, there
was publication bias in the included studies; AUCs of
urinary [TIMP-2] × [IGFBP7] for diagnosing AKI in these
studies might be overestimated to a certain degree. Finally,
the predictive value of urinary [TIMP-2] × [IGFBP7] for
AKI progression and prognosis are also important issues
in clinic. However, we did not directly explore these prob-
lems, owing to limited studies.
Conclusions
On the basis of recent evidence, urinary [TIMP-
2] × [IGFBP7] is an effective predictive factor of AKI.
Further studies should determine how using this test can
affect disease outcomes in the future.
Key messages
 AKI, a common disorder in critically ill patients, is
closely associated with prolonged ICU stay, severe
complications, and increased mortality.
 Urinary [TIMP-2] × [IGFBP7] is an effective predictive
factor of AKI, especially for patients undergoing
cardiac surgery.
 A combined use of biomarkers with clinical
characteristics of patients may help predict AKI in
the future.
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